Loading...
AJANTPHARM logo

Ajanta Pharma LimitedNSEI:AJANTPHARM Aktierapport

Marknadsvärde ₹300.0b
Aktiekurs
₹2.40k
Mitt verkliga värde
₹3.02k
20.6% undervärderad intrinsisk rabatt
1Y-27.8%
7D-2.6%
Portföljens värde
​
Utsikt

Ajanta Pharma Limited

NSEI:AJANTPHARM Aktierapport

Börsvärde: ₹300.0b

Ajanta Pharma (AJANTPHARM) Aktievy

Ajanta Pharma Limited, ett företag verksamt inom formulering av specialiserade läkemedel, utvecklar, tillverkar och marknadsför tillsammans med sina dotterbolag färdiga doser av specialiserade läkemedel. Mer information

AJANTPHARM fundamental analys
Snöflinga Score
Värdering3/6
Framtida tillväxt3/6
Tidigare resultat3/6
Finansiell hälsa6/6
Utdelningar4/6

Belöningar

Intäkterna förväntas växa med 14.98% per år

Intäkterna har ökat 9.1% per år under de senaste 5 åren

Analytiker är överens om att aktiekursen kommer att stiga med 25.9%

Riskanalys

Instabil utdelningshistorik


AJANTPHARM Community Fair Values

Create Narrative

See what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.

AJANTPHARM logo
Ajanta Pharma

Tightening Global Regulations And Supply Risks Will Drag Outlook

Key Takeaways Rising regulatory scrutiny, supply chain risks, and pricing pressures threaten Ajanta Pharma's margins and revenue growth, particularly in emerging and US markets. Heavy dependence on emerging markets and a limited pipeline in complex drugs expose the company to volatility, intense competition, and restricted long-term profit expansion.
View narrative
₹2.04k
FV
17.5% övervärderad intrinsisk rabatt
12.19%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
2 months ago author updated this narrative
AJANTPHARM logo
Ajanta Pharma

Expanding Asian And African Markets Will Drive Secular Growth

Key Takeaways Aggressive investment in new markets, products, and digital infrastructure positions Ajanta for sustained above-industry growth and improved profitability across Asia and Africa. First-mover advantage in chronic and specialty therapeutics, coupled with rising global demand for generics, underpins margin expansion and robust long-term cash flow.
View narrative
₹3.29k
FV
27.1% undervärderad intrinsisk rabatt
13.06%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
2 months ago author updated this narrative
AJANTPHARM logo
Ajanta Pharma

Aging Demographics And Emerging Markets Will Fuel Global Healthcare Demand

Key Takeaways Focus on high-demand therapeutic segments and expansion into emerging markets positions Ajanta Pharma for sustained growth and increased market share. Robust R&D pipeline, manufacturing expansion, and strong financial discipline provide a solid foundation for margin improvement and future growth opportunities.
View narrative
₹3.01k
FV
20.2% undervärderad intrinsisk rabatt
11.57%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
30 days ago author updated this narrative
View Stock Community
HOTH logo
Hoth Therapeutics

100% Patient Improvement in trial puts this $16M Biotech on the radar

Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.

View narrative
19users have liked this narrative
2users have commented on this narrative
132users have followed this narrative
US$5.3
70.2% undervärderad intrinsisk rabatt
Jolt_Communications Fair Value
Revenue growth
N/A
Profit Margin
30%
Future PE
20x
Share price in 2030
US$0

Ajanta Pharma Limited Konkurrenter

Prishistorik och prestanda

Sammanfattning av aktiekursernas upp- och nedgångar samt förändringar för Ajanta Pharma
Historiska aktiekurser
Aktuell aktiekurs₹2,401.80
52 veckors högsta₹3,428.00
52 veckors lägsta₹2,327.30
Beta0.16
1 månads förändring-7.65%
3 månaders förändring-10.90%
1 års förändring-27.76%
3 års förändring90.57%
5 års förändring128.87%
Förändring sedan börsintroduktionen15,234.99%

Senaste nyheter och uppdateringar

Here's Why We Think Ajanta Pharma (NSE:AJANTPHARM) Might Deserve Your Attention Today

Aug 18
Here's Why We Think Ajanta Pharma (NSE:AJANTPHARM) Might Deserve Your Attention Today

Ajanta Pharma Limited (NSE:AJANTPHARM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Jul 31
Ajanta Pharma Limited (NSE:AJANTPHARM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Does Ajanta Pharma (NSE:AJANTPHARM) Have A Healthy Balance Sheet?

Jul 30
Does Ajanta Pharma (NSE:AJANTPHARM) Have A Healthy Balance Sheet?

Recent updates

Here's Why We Think Ajanta Pharma (NSE:AJANTPHARM) Might Deserve Your Attention Today

Aug 18
Here's Why We Think Ajanta Pharma (NSE:AJANTPHARM) Might Deserve Your Attention Today

Ajanta Pharma Limited (NSE:AJANTPHARM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Jul 31
Ajanta Pharma Limited (NSE:AJANTPHARM) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Does Ajanta Pharma (NSE:AJANTPHARM) Have A Healthy Balance Sheet?

Jul 30
Does Ajanta Pharma (NSE:AJANTPHARM) Have A Healthy Balance Sheet?

Ajanta Pharma Limited (NSE:AJANTPHARM) Investors Are Less Pessimistic Than Expected

May 26
Ajanta Pharma Limited (NSE:AJANTPHARM) Investors Are Less Pessimistic Than Expected

If EPS Growth Is Important To You, Ajanta Pharma (NSE:AJANTPHARM) Presents An Opportunity

Mar 29
If EPS Growth Is Important To You, Ajanta Pharma (NSE:AJANTPHARM) Presents An Opportunity

What Ajanta Pharma Limited's (NSE:AJANTPHARM) P/E Is Not Telling You

Feb 20
What Ajanta Pharma Limited's (NSE:AJANTPHARM) P/E Is Not Telling You

Ajanta Pharma Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Feb 02
Ajanta Pharma Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

With EPS Growth And More, Ajanta Pharma (NSE:AJANTPHARM) Makes An Interesting Case

Dec 15
With EPS Growth And More, Ajanta Pharma (NSE:AJANTPHARM) Makes An Interesting Case
User avatar

Branded Generics Growth And Global Expansion Will Accelerate Earnings And Market Share

Ajanta Pharma's strong performance in Branded Generics and effective cash management strategy indicate robust future revenue and margin improvements.

Revenue Beat: Ajanta Pharma Limited Exceeded Revenue Forecasts By 5.3% And Analysts Are Updating Their Estimates

Oct 31
Revenue Beat: Ajanta Pharma Limited Exceeded Revenue Forecasts By 5.3% And Analysts Are Updating Their Estimates

Here's Why Ajanta Pharma (NSE:AJANTPHARM) Has Caught The Eye Of Investors

Sep 10
Here's Why Ajanta Pharma (NSE:AJANTPHARM) Has Caught The Eye Of Investors

We Think Ajanta Pharma (NSE:AJANTPHARM) Can Manage Its Debt With Ease

Aug 23
We Think Ajanta Pharma (NSE:AJANTPHARM) Can Manage Its Debt With Ease

Ajanta Pharma Limited Just Recorded A 11% EPS Beat: Here's What Analysts Are Forecasting Next

Aug 04
Ajanta Pharma Limited Just Recorded A 11% EPS Beat: Here's What Analysts Are Forecasting Next

Some Confidence Is Lacking In Ajanta Pharma Limited's (NSE:AJANTPHARM) P/E

Aug 01
Some Confidence Is Lacking In Ajanta Pharma Limited's (NSE:AJANTPHARM) P/E

With EPS Growth And More, Ajanta Pharma (NSE:AJANTPHARM) Makes An Interesting Case

Jun 01
With EPS Growth And More, Ajanta Pharma (NSE:AJANTPHARM) Makes An Interesting Case

Ajanta Pharma Limited (NSE:AJANTPHARM) Analysts Are Pretty Bullish On The Stock After Recent Results

May 05
Ajanta Pharma Limited (NSE:AJANTPHARM) Analysts Are Pretty Bullish On The Stock After Recent Results

Ajanta Pharma Limited's (NSE:AJANTPHARM) Intrinsic Value Is Potentially 23% Below Its Share Price

Apr 05
Ajanta Pharma Limited's (NSE:AJANTPHARM) Intrinsic Value Is Potentially 23% Below Its Share Price

We Think Ajanta Pharma (NSE:AJANTPHARM) Can Manage Its Debt With Ease

Feb 23
We Think Ajanta Pharma (NSE:AJANTPHARM) Can Manage Its Debt With Ease

Ajanta Pharma Limited (NSE:AJANTPHARM) Investors Are Less Pessimistic Than Expected

Dec 23
Ajanta Pharma Limited (NSE:AJANTPHARM) Investors Are Less Pessimistic Than Expected

Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly

Aug 26
Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly

These 4 Measures Indicate That Ajanta Pharma (NSE:AJANTPHARM) Is Using Debt Reasonably Well

Feb 07
These 4 Measures Indicate That Ajanta Pharma (NSE:AJANTPHARM) Is Using Debt Reasonably Well

Here's Why Ajanta Pharma (NSE:AJANTPHARM) Has Caught The Eye Of Investors

Oct 24
Here's Why Ajanta Pharma (NSE:AJANTPHARM) Has Caught The Eye Of Investors

Estimating The Intrinsic Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)

Aug 25
Estimating The Intrinsic Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)

Is Now The Time To Put Ajanta Pharma (NSE:AJANTPHARM) On Your Watchlist?

Jul 19
Is Now The Time To Put Ajanta Pharma (NSE:AJANTPHARM) On Your Watchlist?

A Look At The Intrinsic Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)

Apr 28
A Look At The Intrinsic Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)

Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly

Mar 14
Ajanta Pharma (NSE:AJANTPHARM) Seems To Use Debt Quite Sensibly

I Built A List Of Growing Companies And Ajanta Pharma (NSE:AJANTPHARM) Made The Cut

Feb 06
I Built A List Of Growing Companies And Ajanta Pharma (NSE:AJANTPHARM) Made The Cut

Estimating The Fair Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)

Dec 13
Estimating The Fair Value Of Ajanta Pharma Limited (NSE:AJANTPHARM)

Ajanta Pharma (NSE:AJANTPHARM) Will Pay A Dividend Of ₹9.50

Oct 31
Ajanta Pharma (NSE:AJANTPHARM) Will Pay A Dividend Of ₹9.50

Here's Why We Think Ajanta Pharma (NSE:AJANTPHARM) Is Well Worth Watching

Sep 22
Here's Why We Think Ajanta Pharma (NSE:AJANTPHARM) Is Well Worth Watching

Is Ajanta Pharma Limited (NSE:AJANTPHARM) Trading At A 27% Discount?

Sep 08
Is Ajanta Pharma Limited (NSE:AJANTPHARM) Trading At A 27% Discount?

Does Ajanta Pharma (NSE:AJANTPHARM) Have A Healthy Balance Sheet?

Aug 26
Does Ajanta Pharma (NSE:AJANTPHARM) Have A Healthy Balance Sheet?

Here's Why Shareholders Will Not Be Complaining About Ajanta Pharma Limited's (NSE:AJANTPHARM) CEO Pay Packet

Jul 07
Here's Why Shareholders Will Not Be Complaining About Ajanta Pharma Limited's (NSE:AJANTPHARM) CEO Pay Packet

Should You Be Adding Ajanta Pharma (NSE:AJANTPHARM) To Your Watchlist Today?

Jun 14
Should You Be Adding Ajanta Pharma (NSE:AJANTPHARM) To Your Watchlist Today?

Is Ajanta Pharma Limited (NSE:AJANTPHARM) Trading At A 30% Discount?

May 15
Is Ajanta Pharma Limited (NSE:AJANTPHARM) Trading At A 30% Discount?

Ajanta Pharma Limited (NSE:AJANTPHARM) Vies For A Place In Your Dividend Portfolio: Here's Why

Apr 10
Ajanta Pharma Limited (NSE:AJANTPHARM) Vies For A Place In Your Dividend Portfolio: Here's Why

Ajanta Pharma Limited's (NSE:AJANTPHARM) Has Had A Decent Run On The Stock market: Are Fundamentals In The Driver's Seat?

Mar 11
Ajanta Pharma Limited's (NSE:AJANTPHARM) Has Had A Decent Run On The Stock market: Are Fundamentals In The Driver's Seat?

Does Ajanta Pharma (NSE:AJANTPHARM) Deserve A Spot On Your Watchlist?

Feb 24
Does Ajanta Pharma (NSE:AJANTPHARM) Deserve A Spot On Your Watchlist?

Aktieägarnas avkastning

AJANTPHARMIN PharmaceuticalsIN Marknad
7D-2.6%1.4%1.5%
1Y-27.8%-7.2%-4.7%

Avkastning vs industri: AJANTPHARM presterade sämre än Indian Pharmaceuticals branschen som gav -7.2 % under det senaste året.

Avkastning vs Marknaden: AJANTPHARM presterade sämre än Indian marknaden som gav -4.7 % under det senaste året.

Prisvolatilitet

Is AJANTPHARM's price volatile compared to industry and market?
AJANTPHARM volatility
AJANTPHARM Average Weekly Movement3.2%
Pharmaceuticals Industry Average Movement5.0%
Market Average Movement5.2%
10% most volatile stocks in IN Market8.3%
10% least volatile stocks in IN Market3.2%

Stabil aktiekurs: AJANTPHARM har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för Indian.

Volatilitet över tid: AJANTPHARM s veckovolatilitet ( 3% ) har varit stabil under det senaste året.

Om företaget

GrundadAnställdaVD OCH KONCERNCHEFWebbplats
19739,628Yogesh Agrawalwww.ajantapharma.com

Ajanta Pharma Limited, ett företag som utvecklar specialiserade läkemedelsberedningar, utvecklar, tillverkar och marknadsför tillsammans med sina dotterbolag färdiga doseringar för specialiserade läkemedel. Företaget marknadsför och betjänar olika terapeutiska segment, t.ex. kardiologi, antidiabetika, oftalmologi, dermatologi, smärtlindring och andningsvägar. Företaget tillhandahåller också tabletter, kapslar, injicerbara läkemedel, inhalatorer, salvor, krämer och vätskor.

Ajanta Pharma Limited Sammanfattning av grunderna

Hur förhåller sig Ajanta Pharma:s resultat och omsättning till dess börsvärde?
AJANTPHARM grundläggande statistik
Börsvärde₹299.96b
Vinst(TTM)₹9.30b
Intäkter(TTM)₹48.06b
32.3x
P/E-förhållande
6.2x
P/S-förhållande

Är AJANTPHARM övervärderat?

Se Verkligt värde och värderingsanalys

Resultat & intäkter

Viktig lönsamhetsstatistik från den senaste resultatrapporten (TTM)
AJANTPHARM resultaträkning (TTM)
Intäkter₹48.06b
Kostnad för intäkter₹11.51b
Bruttovinst₹36.55b
Övriga kostnader₹27.25b
Intäkter₹9.30b

Senast redovisade vinst

Jun 30, 2025

Nästa vinstdatum

n/a

Vinst per aktie (EPS)74.46
Bruttomarginal76.05%
Nettovinstmarginal19.35%
Skuld/egenkapitalförhållande1.3%

Hur har AJANTPHARM utvecklats på lång sikt?

Se historisk utveckling och jämförelse

Utdelningar

1.2%
Aktuell utdelningsavkastning
38%
Utbetalningskvot

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2025/10/04 02:30
Aktiekurs vid dagens slut2025/10/03 00:00
Intäkter2025/06/30
Årlig intjäning2025/03/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om den analysmodell som används för att generera denna rapport finns på vår Github-sida, vi har också guider om hur man använder våra rapporter och tutorials på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Ajanta Pharma Limited bevakas av 26 analytiker. 13 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
Rashmi Sancheti ShettyAnand Rathi Shares and Stock Brokers Limited
null nullAnand Rathi Shares and Stock Brokers Limited
null nullAsian Markets Securities Private Limited